title: Preliminary data of the antipancreatic tumor efficacy and toxicity of long-circulating and pH-sensitive liposomes containing cisplatin.
abstract: OBJECTIVE
  Pancreatic cancer is the fourth most common cause of cancer-related death in the USA. This is mainly because of the chemoresistance of this type of tumor; thus, the development of novel therapeutic modalities is needed.
  
  
  METHODS
  Long-circulating and pH-sensitive liposomes containing cisplatin (SpHL-CDDP) were administered systemically into pancreatic tumor-bearing mice for a period of 14 days. The antitumor efficacy and toxicity of this new treatment method on the basis of cisplatin-loaded liposomes was compared with the classical free-CDDP method. Tc-HYNIC-βAla-bombesin(7-14) tumor uptake and histopathologic findings were used to monitor and compare the two treatment modalities.
  
  
  RESULTS
  The antitumor activity of SpHL-CDDP treatment was shown by (a) decrease in tumor volume, (b) development of tumor necrotic areas, and (c) decrease in Tc-HYNIC-βAla-bombesin(7-14) tumor uptake. Toxicity was evaluated by the development of inflammation and necrotic areas in the kidneys, liver, spleen, and intestine: toxic effects were greater with free-CDDP than SpHL-CDDP.
  
  
  CONCLUSIONS
  SpHL-CDDP showed significant antitumor activity in pancreatic cancer-bearing mice, with lower toxicity in comparison with free-CDDP.
authors.affiliation: aDepartment of Clinical and Toxicological Analyses bDepartment of Pharmaceutical Products, Faculty of Pharmacy cDepartment of Pathology, Biological Science Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil dDepartment of Nuclear Medicine, Santa Maria della Misericordia Hospital, Rovigo, Italy eDepartment of Nuclear Medicine, University of Southern California, Los Angeles, California, USA.
authors.forename: Fernanda N
authors.initials: FN
authors.lastname: Carlesso
authors.forename: Raquel S
authors.initials: RS
authors.lastname: Araújo
authors.forename: Leonardo L
authors.initials: LL
authors.lastname: Fuscaldi
authors.forename: Sued E
authors.initials: SE
authors.lastname: Mendes Miranda
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
authors.forename: Cláudia S
authors.initials: CS
authors.lastname: Teixeira
authors.forename: Diego C
authors.initials: DC
authors.lastname: Dos Reis
authors.forename: Elaine A
authors.initials: EA
authors.lastname: Leite
authors.forename: Josianne N
authors.initials: JN
authors.lastname: Silveira
authors.forename: Simone O A
authors.initials: SO
authors.lastname: Fernandes
authors.forename: Geovanni D
authors.initials: GD
authors.lastname: Cassali
authors.forename: Mônica C
authors.initials: MC
authors.lastname: de Oliveira
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Colletti
authors.forename: André L B
authors.initials: AL
authors.lastname: de Barros
authors.forename: Valbert N
authors.initials: VN
authors.lastname: Cardoso
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000737:chemistry; D001839:Bombesin / Q000031:analogs & derivatives; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D004058:Diffusion; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008081:Liposomes / Q000008:administration & dosage / Q000097:blood* / Q000737:chemistry*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D015609:Organotechnetium Compounds; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D010865:Pilot Projects; D019275:Radiopharmaceuticals; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D008081:Liposomes; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C000606095:technetium 99m HYNIC-beta-Ala-bombesin(7-14); D001839:Bombesin; D002945:Cisplatin